"name","label","description","instanceType","rationale","id","uuid:ID"
"Study Design 1","","The main design for the study","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","a24df79c-2fed-4994-9ab8-873675e10c1e"
